A personalized cancer vaccine may sound more like fiction than reality to some. However, researchers from Mount Sinai Hospital report they’ve developed just that with the help of a computational platform. Even better, these personalized vaccines — treating forms of the disease including lung and bladder cancer — appear safe for use and beneficial for patients at high risk of recurrence. These findings come from the initial results of a phase-1 clinical trial involving the vaccines.
“While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments,” says study author Thomas Marron, MD, PhD, Assistant Director for Early Phase and Immunotherapy Trials at The Tisch Cancer Institute and Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, in a media release. “Cancer vaccines, which typically combine tumor-specific targets that the immune system can learn to recognize and attack to prevent recurrence of cancer. The vaccine also contains an adjuvant that primes the immune system to maximize the efficacy.”